Clinical supply optimization – mid-size pharma rejects bulk, avoids shortage

Clinical supply optimization – mid-size pharma rejects bulk, avoids shortage

Many companies developing biosimilars are not confident in their own capacity to forecast supply needs and manage them on an ongoing basis. Read this case study to learn how after just two weeks, our Thermo Fisher Scientific’s Clinical Supply Optimization team was able to deliver a plan with estimates that were extremely close to the numbers the sponsor had developed.

Resource Library

Additional Resources